| Literature DB >> 35959454 |
Jing Song1,2, Chenye Jin3, Zhongyan Shan1, Weiping Teng1, Jing Li1.
Abstract
Background and Objetives: Hyperuricemia (HUA) and gout seriously influence patients' quality of life. The current study was performed to investigate the prevalence of HUA and gout and the related risk factors in Chinese adults.Entities:
Keywords: China; epidemiology; gout; hyperuricemia; prevalence
Year: 2022 PMID: 35959454 PMCID: PMC9328039 DOI: 10.2478/jtim-2022-0031
Source DB: PubMed Journal: J Transl Int Med ISSN: 2224-4018
Figure 1Distribution of serum uric acid levels in males and females. Std. Dev: standard deviation.
Age- and sex-standardized prevalence rates of hyperuricemia and gout in mainland China
| Prevalence of gout, % (95% CI) | Prevalence of hyperuricemia, % (95 % CI) | |||||
|---|---|---|---|---|---|---|
| Overall | Males | Females | Overall | Males | Females | |
|
|
|
|
|
|
|
|
|
| ||||||
| Urban | 3.7 (2.8–4.9) | 5.2 (4.2–6.5) | 2.2 (1.7–2.8) | 19.7 (14.9–25.6) | 25.8 (20.6–31.9) | 13.4 (8.9–19.7) |
| Rural | 2.7 (2.0–3.8) | 3.6 (2.7–4.9) | 1.8 (1.2–2.6) | 15.6 (12.7–19.0) | 21.1 (17.2–25.6) | 10.0 (7.9–12.5) |
| P for difference | 0.42 | 0.20 | 0.90 | 0.30 | 0.25 | 0.41 |
|
| ||||||
| Inland | 3.4 (2.9–3.9) | 4.5 (3.9–5.3) | 1.7 (1.3–2.1) | 16.8 (15.3–18.3) | 22.8 (20.1–24.9) | 10.6 (9.4–11.8) |
| Coastal | 3.1 (2.4–3.9) | 4.3 (3.6–5.3) | 1.4 (0.9–2.2) | 19.0 (14.5–25.0) | 24.5 (19.8–29.9) | 13.4 (8.7–20.1) |
| P for difference | 0.46 | 0.62 | 0.37 | 0.39 | 0.54 | 0.30 |
|
| ||||||
| Below high school | 2.9 (2.6–3.4) | 3.8 (3.2–4.4) | 2.1 (1.7–2.5) | 16.1 (14.4–18.0) | 20.7 (18.6–23.0) | 11.4 (9.5–13.6) |
| High school and above | 3.5 (3.1–4.1) | 5.2 (4.6–5.9) | 1.9 (1.3–2.6) | 18.8 (15.7–22.3) | 25.0 (22.0–28.2) | 12.5 (9.1–17.0) |
| P for difference |
| 0.22 |
|
|
| 0.54 |
|
| ||||||
| No smoking | 3.3 (3.0–3.8) | 4.7 (4.2–5.2) | 2.0 (1.6–2.4) | 17.6 (15.5–20.0) | 23.6 (21.4–25.9) | 11.6 (9.3–14.3) |
| Smoking | 3.7 (2.9–4.7) | 4.2 (3.6–4.9) | 3.2 (2.1–4.9) | 22.4 (18.0–22.4) | 23.5 (20.9–26.4) | 16.6 (14.0–19.5) |
| P for difference |
| 0.82 |
|
| 0.35 |
|
|
| ||||||
| Han | 3.2 (2.8–3.6) | 4.3 (3.8–4.9) | 2.0 (1.6–2.5) | 17.9 (15.6–20.5) | 23.9 (21.5–26.6) | 11.8 (9.5–14.7) |
| Tibetan | 11.8 (9.6–14.4 | ) 9.8 (9.1–10.7) | 13.8 (9.1–20.5) | 17.0 (15.5–18.6) | 22.9 (22.5–23.4) | 10.9 (8.4–13.9) |
| Zhuang | 5.2 (3.4–8.1)* | 8.8 (6.3– | 1.6 (0.5–4.6) | 16.4 (12.2–21.7) | 21.8 (18.5–25.4) | 10.9(6.1–18.6) |
| 12.2)* | ||||||
| Uyghur | 1.7 (1.1–2.6)* | 2.1 (1.9–2.2)* | 1.3 (0.5–3.5) | 4.6 (1.6–12.4)* | 4.0 (2.5–6.3)* | 5.3 (1.18–20.5) |
| Hui | 0.8 (0.6–1.0) | 0.6 (0.5–0.9) | 0.9 (0.7–1.2) | 4.0 (3.6–4.4) | 5.9 (5.9–6.0) | 2.0 (1.4–2.8) |
| P for difference |
|
| 0.50 |
|
| 0.23 |
|
| ||||||
| 18–29 | 1.0 (0.7–1.3) | 1.1 (0.8–1.5) | 0.8 (0.5–1.3) | 20.0 (16.7–23.8) | 28.4 (24.5–32.6) | 11.5 (8.5–15.4) |
| 30–39 | 2.3 (1.8–2.9) | 3.4 (2.9–4.1) | 1.0 (0.6–1.8) | 17.4 (14.5–20.7) | 26.0 (23.2–29.1) | 8.3 (5.4–12.7) |
| 40–49 | 3.4 (2.9–3.9) | 5.0 (4.2–5.9) | 1.7(1.3–2.1) | 15.5 (13.5–17.6) | 22.3 (20.0–24.9) | 8.3 (6.2–11.1) |
| 50–59 | 5.2 (4.4–6.1) | 7.0 (5.9–8.3) | 3.2 (2.6–4.1) | 16.7 (15.1–18.5) | 19.2 (17.0–21.5) | 14.1 (12.3–16.2) |
| 60–69 | 5.9 (5.0–6.8) | 7.5 (6.5–8.8) | 4.1 (3.0–5.7) | 17.0 (14.8–19.3) | 18.3 (16.4–20.3) | 15.6 (12.8–18.9) |
| ≥70 | 6.1 (5.1–7.3) | 8.2 (6.5–10.2) | 4.3 (3.2–5.7) | 19.9 (18.0–21.9) | 18.6 (16.6–20.8) | 21.0 (18.8–23.2) |
| P for trend |
|
|
|
|
|
|
|
| ||||||
| <18.5 | 1.6 (1.0–2.5) | 1.5 (0.8–2.5) | 1.7 (0.9–3.4) | 9.0 (5.7–14.0) | 11.7 (8.2–16.3) | 6.3 (2.7–14.0) |
| 18.5–23.9 | 2.6 (2.2–3.1) | 3.4 (2.7–4.1) | 1.9 (1.5–2.3) | 13.0 (10.5–16.0) | 17.6 (14.8–20.7) | 8.4 (6.1–11.4) |
| 24.0–27.9 | 3.4 (3.0–4.0) | 4.8 (4.3–5.4) | 2.0 (1.5–2.7) | 20.4 (17.9–23.1) | 25.6 (22.7–28.8) | 15.0 (12.7–17.7) |
| ≥28.0 | 4.9 (4.1–5.8) | 6.9 (5.7–8.4) | 2.9 (2.2–3.8) | 31.4 (29.0–33.9) | 32.6 (34.4–38.8) | 26.1 (22.5–30.0) |
| P for trend |
|
| 0.32 |
|
|
|
|
| ||||||
| <5000 | 4.2 (3.0–5.8) | 5.4 (3.9–7.4) | 2.9 (1.6–5.1) | 18.3 (14.6–22.7) | 22.7 (19.5–26.4) | 13.8 (9.0–20.6) |
| 5000–10,000 | 2.9 (2.2–3.8) | 4.0 (2.9–5.4) | 1.8 (1.3–2.5) | 17.7 (13.9–22.2) | 23.8 (19.1–29.3) | 11.4 (8.1–15.8) |
| 10,000–30,000 | 2.8 (2.4–3.2) | 3.6 (3.0–4.2) | 2.0 (1.5–2.5) | 16.4 (14.5–18.4) | 21.6 (19.4–23.9) | 11.0 (9.0–13.5) |
| 30,000–50,000 | 2.8 (2.4–3.4) | 3.6 (3.0–4.3) | 2.0 (1.5–2.8) | 17.0 (15.5–18.5) | 22.8 (21.1–24.6) | 11.0 (9.5–12.7) |
| 50,000–100,000 | 3.7 (3.2–4.2) | 5.5 (4.9–6.2) | 1.9 (1.3–2.6) | 18.0 (15.3–21.0) | 23.9 (21.0–27.1) | 11.9 (9.3–15.2) |
| >100,000 | 4.0 (3.5–4.6) | 6.2 (5.3–7.1) | 1.9 (1.4–2.4) | 21.4 (17.6–25.9) | 28.5 (23.9–33.6) | 14.3 (10.7–18.7) |
| P for trend |
|
| 0.32 |
|
|
|
BMI: body mass index; CNY: Chinese yuan (1 CNY = 0.1489 USD); (U): u-shaped curve trend; 95% CI: 95% confidence interval.
aThe prevalence rate within each subgroup was compared by the chi-square test.
bThe trend of prevalence rate within each subgroup was analyzed through Cochran-Armitage test for trend.
*Compared with Han people, the differences were statistically significant, in which P was less than the adjusted cutoff value (0.05/4 = 0.0125) due to multiple comparisons by the chi-square test.
Distribution of serum uric acid level analyzed by subgroups
| Serum uric acid level, mean ± SD (μmol/L) | |||
|---|---|---|---|
| Overall | Males | Females | |
|
| |||
| Urban | 319.76 ± 93.41 | 368.19 ± 88.33 | 274.86 ± 73.41 |
| Rural | 308.63 ± 94.56 | 352.02 ± 93.86 | 266.47 ± 73.92 |
| P for difference |
|
|
|
|
| |||
| Inland | 312.62 ± 93.37 | 358.90 ± 90.77 | 269.26 ± 72.65 |
| Coastal | 319.32 ± 95.74 | 364.51 ± 92.57 | 275.31 ± 76.29 |
| P for difference |
|
|
|
|
| |||
| Below high school | 304.04 ± 91.92 | 346.17 ± 91.60 | 270.31 ± 77.07 |
| High school and above | 323.53 ± 95.05 | 371.05 ± 89.78 | 271.59 ± 70.24 |
| P for difference |
|
| 0.09 |
|
| |||
| No smoking | 299.27 ± 89.85 | 359.06 ± 91.40 | 270.48 ± 73.42 |
| Smoking | 357.54 ± 92.54 | 362.13 ± 91.29 | 286.61 ± 82.16 |
| P for difference |
| 0.94 |
|
|
| |||
| 18–29 | 321.94 ± 96.46 | 373.36 ± 91.03 | 268.42 ± 68.92 |
| 30–39 | 311.64 ± 97.41 | 369.27 ± 90.12 | 257.68 ± 68.92 |
| 40–49 | 306.18 ± 93.91 | 356.79 ± 91.05 | 259.57 ± 69.09 |
| 50–59 | 314.11 ± 89.98 | 350.02 ± 90.39 | 282.02 ± 76.49 |
| 60–69 | 317.27 ± 89.17 | 348.17 ± 90.04 | 288.66 ± 78.15 |
| ≥70 | 320.70 ± 91.51 | 344.52 ± 92.33 | 298.70 ± 85.03 |
| P for trend |
|
|
|
|
| |||
| <18.5 | 280.04 ± 80.72 | 330.99 ± 80.80 | 251.22 ± 64.89 |
| 18.5–23.9 | 295.46 ± 86.49 | 343.68 ± 85.25 | 259.43 ± 67.86 |
| 24.0–27.9 | 329.34 ± 94.23 | 367.58 ± 90.37 | 282.81 ± 76.17 |
| ≥28.0 | 355.77 ± 102.01 | 393.08 ± 99.04 | 304.05 ± 81.42 |
| P for trend |
|
|
|
|
| |||
| <5000 | 302.84 ± 92.26 | 347.54 ± 92.83 | 271.36 ± 77.72 |
| 5000–10,000 | 302.81 ± 93.60 | 346.72 ± 94.44 | 267.01 ± 76.03 |
| 10,000–30,000 | 306.10 ± 92.37 | 350.02 ± 92.17 | 268.97 ± 74.53 |
| 30,000–50,000 | 316.24 ± 93.24 | 361.39 ± 90.37 | 272.17 ± 72.65 |
| 50,000–100,000 | 324.06 ± 93.25 | 369.00 ± 86.96 | 272.76 ± 71.09 |
| >100,000 | 331.90 ± 98.72 | 380.59 ± 91.54 | 273.70 ± 71.82 |
| P for trend |
|
|
|
|
| |||
| Han | 318.65 ± 93.64 | 364.56 ± 90.24 | 274.40 ± 73.34 |
| Tibetan | 298.24 ± 88.26* | 362.03 ± 79.93 | 261.58 ± 70.12* |
| Zhuang | 315.54 ± 91.60 | 363.68 ± 88.11 | 268.42 ± 67.22 |
| Uyghur | 243.22 ± 82.73* | 268.60 ± 88.42* | 221.28 ± 70.49* |
| Hui | 258.71 ± 80.46* | 301.64 ± 74.65* | 215.57 ± 60.57* |
| P for difference |
|
|
|
ANOVA: analysis of variance; BMI: body mass index; CNY: Chinese yuan (1 CNY = 0.1489 USD); SD: standard deviation; SUA: serum uric acid; (U): u-shaped curve trend.
aThe SUA level within each subgroup was compared by the independent sample t-test.
bThe trend test of SUA level within each subgroup was analyzed through one-way ANOVA.
cThe SUA level among the five ethnic groups was compared through one-way ANOVA followed by post hoc Bonferroni correction.
*Compared with Han people, the differences were statistically significant.
Figure 2Regional distribution of the prevalence of HUA in mainland China: (A) prevalence in males (%); (B) prevalence in females (%). HUA: hyperuricemia.
Figure 3Regional distribution of the prevalence of gout in mainland China: (A) prevalence in males (%); (B) prevalence in females (%).
Multiple logistic regression analysis of the associated factors with hyperuricemia and gout
| Risk factors | Hyperuricemia | Gout | ||||||
|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||||
|
| ||||||||
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
|
| 0.84 (0.82–0.85) | <0.01 | 1.01 (0.98–1.04) | 0.44 | 1.44 (1.38–1.50) | <0.01 | 1.37 (1.29–1.45) | <0.01 |
|
| 1.16 (1.09–1.24) | <0.01 | 1.25 (1.15–1.36) | <0.01 | 1.28 (1.12–1.46) | <0.01 | 0.84 (0.69–1.01) | 0.07 |
|
| 0.99 (0.94–1.04) | 0.59 | 1.54 (1.30–1.82) | <0.01 | 1.04 (0.92–1.16) | 0.55 | 1.17 (0.81–1.69) | 0.40 |
|
| 1.13 (1.07–1.20) | <0.01 | 1.23 (1.14–1.33) | <0.01 | 1.30 (1.14–1.47) | <0.01 | 1.04 (0.88–1.22) | 0.69 |
|
| 1.09 (1.03–1.15) | <0.01 | 1.25 (1.16–1.34) | <0.01 | 1.05 (0.93–1.18) | 0.48 | 0.65 (0.54–0.78) | <0.01 |
| Hana | 2.07(1.85–2.32) | <0.01 | 1.76 (1.53–2.02) | <0.01 | 0.59 (0.49–0.72) | <0.01 | 0.56 (0.45–0.68) | <0.01 |
| Tibetanb | 1.11(0.91–1.36) | 0.32 | 1.01(0.81–1.26) | 0.93 | 3.60(2.73–4.76) | <0.01 | 4.89(3.85–6.21) | <0.01 |
| Zhuangc | 0.12(0.08–0.17) | <0.01 | 0.27(0.20-0.37) | <0.01 | 0.36(0.18–0.71) | <0.01 | 0.41(0.21–0.80) | 0.01 |
| Uyghurd | 0.25(0.19–0.34) | <0.01 | 0.21(0.13–0.35) | <0.01 | 0.22(0.10–0.49) | <0.01 | 0.31(0.14–0.66) | <0.01 |
| Huie | 0.99(0.83–1.18) | 0.87 | 1.03(0.82–1.30) | 0.80 | 3.08(2.31–4.12) | <0.01 | 1.11(0.62–1.99) (2.23-3.73) | 0.73 |
|
| ||||||||
| ≤5000 (reference) | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| 5000–10,000 | 1.03 (0.90–1.17) | 0.70 | 0.93 (0.81–1.07) | 0.33 | 0.81 (0.62–1.05) | 0.11 | 1.02 (0.80–1.31) | 0.86 |
| 10,000–30,000 | 0.93 (0.83–1.04) | 0.17 | 0.84 (0.74–0.94) | <0.01 | 0.80 (0.64–1.00) | 0.06 | 0.78 (0.62–0.99) | 0.04 |
| 30,000–50,000 | 0.94 (0.85–1.05) | 0.30 | 0.84 (0.75–0.96) | <0.01 | 0.79 (0.63–0.99) | 0.06 | 0.77 (0.57–1.00) | 0.04 |
| 50,000–100,000 | 0.97 (0.87–1.09) | 0.67 | 0.83 (0.73–0.95) | <0.01 | 1.06 (0.84–1.33) | 0.59 | 0.75 (0.57–1.00) | 0.05 |
| >100,000 | 1.08 (0.96–1.22) | 0.19 | 0.92 (0.79–1.07) | 0.29 | 1.39 (1.09–1.78) | <0.01 | 0.93 (0.66–1.30) | 0.66 |
| 1.00 | 1.00 | 1.00 | 1.00 | |||||
| <18.5 | 0.82 (0.69–0.97) | 0.02 | 0.85 (0.70–1.04) | 0.11 | 0.63 (0.38–1.05) | 0.08 | 0.94 (0.65–1.39) | 0.76 |
| 24.0–27.9 | 1.20 (1.12–1.29) | <0.01 | 1.47 (1.35–1.61) | <0.01 | 1.10 (0.94–1.28) | 0.24 | 0.97 (0.81–1.18) | 0.78 |
| ≥28.0 | 1.63 (1.48–1.78) | <0.01 | 2.12 (1.88–2.39) | <0.01 | 1.37 (1.12–1.66) | <0.01 | 1.09 (0.84–1.41) | 0.51 |
|
| 0.85 (0.78–0.92) | <0.01 | 1.65 (1.50–1.81) | <0.01 | 1.25 (1.08–1.44) | <0.01 | 1.32 (1.08–1.61) | <0.01 |
|
| 1.11 (1.03–1.20) | 0.01 | 1.20 (1.07–1.34) | <0.01 | 1.08 (0.91–1.28) | 0.40 | 0.78 (0.59–1.03) | 0.07 |
|
| 1.42 (1.29–1.56) | <0.01 | 1.42 (1.27–1.59) | <0.01 | 1.35 (1.12–1.62) | <0.01 | 1.16 (0.91–1.48) | 0.23 |
|
| 1.22 (1.15–1.29) | <0.01 | 1.22 (1.13–1.33) | <0.01 | 1.16 (1.03–1.31) | 0.02 | 0.94 (0.79–1.12) | 0.49 |
|
| ||||||||
| High TG | 1.77 (1.67–1.87) | <0.01 | 1.73 (1.60-1.87) | <0.01 | 1.62 (1.43–1.84) | <0.01 | 1.17 (0.98–1.40) | 0.08 |
| High TC | 1.35 (1.25–1.45) | <0.01 | 1.45 (1.32-1.60) | <0.01 | 1.23 (1.06–1.43) | <0.01 | 1.50 (1.23–1.80) | <0.01 |
| High LDL | 1.14 (1.06–1.23) | <0.01 | 1.20 (1.09-1.33) | <0.01 | 1.02 (0.88–1.19) | 0.78 | 0.82 (0.67–1.01) | 0.06 |
| Low HDL | 1.23 (1.15–1.32) | <0.01 | 1.40 (1.29-1.51) | <0.01 | 1.27 (1.10–1.50) | <0.01 | 0.90 (0.76–1.08) | 0.26 |
|
| 1.30 (1.21–1.39) | <0.01 | 1.32 (1.20-1.44) | <0.01 | 1.23 (1.06–1.42) | <0.01 | 1.16 (0.96–1.41) | 0.13 |
OR: odds ratio; 95% CI: 95% confidence interval; BMI: body mass index; CNY: Chinese yuan (1 CNY = 0.1489 USD); IFG: impaired fasting glucose; IGT: impaired glucose tolerance; TG: triglyceride; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
aAs compared with other ethnic groups including Tibetan, Zhuang, Uyghur, and Hui.
bAs compared with other ethnic groups including Han, Zhuang, Uyghur, and Hui.
cAs compared with other ethnic groups including Han, Tibetan, Uyghur, and Hui.
dAs compared with other ethnic groups including Han, Tibetan, Zhuang, and Hui.
eAs compared with other ethnic groups including Han, Tibetan, Zhuang, and Uyghur.
PAR% of each ethnic group for the prevalence of hyperuricemia and gout
| Ethnic groups | Hyperuricemia | Gout | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||||||||
|
| ||||||||||||
| pd (%) | OR | PAR% (%) | pd (%) | OR | PAR% (%) | pd (%) | OR | PAR% (%) | pd (%) | OR | PAR% (%) | |
| Han | 94.22 | 2.07 | 48.70 | 92.94 | 1.76 | 40.13 | 86.88 | 0.59 | -60.37 | 80.33 | 0.56 | -63.12 |
| Tibetan | - | - | - | - | - | - | 6.77 | 3.60 | 4.89 | 15.85 | 4.89 | 12.61 |
| Zhuang | 0.45 | 0.12 | -3.27 | 1.05 | 0.27 | -2.83 | 0.63 | 0.36 | -1.12 | 1.07 | 0.41 | -1.54 |
| Uyghur | 0.57 | 0.25 | -1.72 | 0.39 | 0.21 | -1.46 | 0.42 | 0.22 | -1.48 | 0.95 | 0.31 | -2.12 |
| Hui | - | - | - | - | 5.30 | 3.08 | 3.58 | - | - | - | ||
pd: proportion of cases exposed to risk factor; OR: odds ratio; PAR%: population attribute risk percent; which was calculated using the following formula: [PAR% = pd(RR - 1/RR)] according to the literature[; -: not an independent risk or a protective factor in multiple logistic regression analysis; RR: relative risk.
Collinearity statistics analysis of the potential related factors with hyperuricemia and gout
| Risk factors | Hyperuricemia | Gout | ||
|---|---|---|---|---|
| Male | Female | Male | Female | |
|
| ||||
| VIF | VIF | VIF | VIF | |
| Age | 1.393 | 1.679 | 1.400 | 1.699 |
| High school and above | 1.370 | 1.495 | 1.377 | 1.516 |
| Current smoking | 1.032 | 1.006 | 1.033 | 1.005 |
| Urban residency | 1.169 | 1.218 | 1.181 | 1.232 |
| Coastal residency | 1.024 | 1.029 | 1.028 | 1.036 |
| Ethnicities | 1.065 | 1.060 | 1.079 | 1.077 |
| Income (CNY/year) | 1.232 | 1.235 | 1.239 | 1.253 |
| BMI (kg/m2) | 1.814 | 1.671 | 1.809 | 1.667 |
| Diabetes | 1.146 | 1.166 | 1.149 | 1.164 |
| IFG | 1.053 | 1.039 | 1.056 | 1.041 |
| IGT | 1.051 | 1.051 | 1.051 | 1.050 |
| Hypertension | 1.155 | 1.235 | 1.158 | 1.233 |
| High TG | 1.279 | 1.248 | 1.280 | 1.252 |
| High TC | 1.828 | 1.818 | 1.839 | 1.840 |
| High LDL | 1.741 | 1.174 | 1.753 | 1.740 |
| Low HDL | 1.133 | 1.156 | 1.138 | 1.152 |
| Abdominal obesity | 1.754 | 1.681 | 1.750 | 1.674 |
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; TG: triglyceride; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; VIF: variance inflation factor.
Multicollinearity was considered to exist if VIF >5.